To describe the overall survival of advanced NSCLC in Latin America.

• To describe demographic and socioeconomic characteristics of patients newly diagnosed with advanced NSCLC
• To describe diagnostic methods, pathological profile and disease stage at diagnosis of advanced NSCLC
• To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC
• To describe treatment responses, progression and survival times.
• To describe reasons for treatment discontinuation
• To identify associations between patient demographics, socioeconomic, pathology, treatment sequences and overall survival;
• To define the patient experience of advanced NSCLC and identify unmet needs in their diagnose and treatment.

Inclusion Criteria:

1. Patients aged 18 years or older;

2. Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time);

3. Histologically or cytologically confirmed advanced NSCLC:

   1. Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery);
   2. Stage IV metastatic disease (de novo or distant relapse)

4. Any NSCLC histological subtype and molecular mutation;

5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;

6. Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care;

7. Access to patient medical chart for data collection;

8. Willing and able to provide written informed consent and privacy authorization for the release of personal health information.

The LATINO Lung study will prospectively recruit a minimum of 700 and up to 800 patients with advanced NSCLC, including locally advanced disease not amenable to curative treatment or metastatic disease from sites in Argentina, Brazil, Chile, Colombia, and Mexico. Other countries may be invited to participate.

Patients will be recruited during an initial study period of 3 months, or more to reach the study minimum sample size, and will be followed for 3 years.